2359O Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)

A.O. Siefker-Radtke, N. Matsubara, S.H. Park, R.A. Huddart, E.F. Burgess, M. Ozguroglu,B. Perez Valderrama, S. Triantos, S. Akapame, Y. Kean, K. Deprince, S. Mukhopadhyay, Y. Loriot

Annals of Oncology（2023）

引用 0|浏览0